Literature DB >> 3909681

Development and characterization of cold-adapted viruses for use as live virus vaccines.

H F Maassab, D C DeBorde.   

Abstract

Representative viruses from twelve RNA and two DNA virus genera have been successfully adapted to growth at sub-optimal temperature (cold-adapted). In almost every case, there was a correlation between acquisition of the cold-adaptation phenotype and loss of virulence in the normal host whether animal or man. Overall, the best method of cold adaptation to develop a live virus vaccine line appeared to be a stepwise lowering of the growth temperature allowing time for multiple lesions to occur and/or be selected. In addition, the starting virus should be a recent isolate not as yet adapted to a tissue culture host and the cold-adaptation process should then occur in a host heterologous to the virus' normal host. These viruses have been reviewed in the light of their cold-adaptation method and successful production of an attenuated line as virus vaccine candidate. Finally, detailed information is presented for the cold-adaptation process in influenza virus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3909681     DOI: 10.1016/0264-410x(85)90124-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial.

Authors:  T A Cha; K Kao; J Zhao; P E Fast; P M Mendelman; A Arvin
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.

Authors:  E L Anderson; F K Newman; H F Maassab; R B Belshe
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

Review 3.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

4.  New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

Authors:  M A Hoelscher; L Jayashankar; S Garg; V Veguilla; X Lu; N Singh; J M Katz; S K Mittal; S Sambhara
Journal:  Clin Pharmacol Ther       Date:  2007-10-24       Impact factor: 6.875

5.  Essential genes from Arctic bacteria used to construct stable, temperature-sensitive bacterial vaccines.

Authors:  Barry N Duplantis; Milan Osusky; Crystal L Schmerk; Darrell R Ross; Catharine M Bosio; Francis E Nano
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

6.  Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66.

Authors:  Erich Hoffmann; Kutubuddin Mahmood; Zhongying Chen; Chin-Fen Yang; Joshua Spaete; Harry B Greenberg; M Louise Herlocher; Hong Jin; George Kemble
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Rescue of influenza B virus from eight plasmids.

Authors:  Erich Hoffmann; Kutubuddin Mahmood; Chin-Fen Yang; Robert G Webster; Harry B Greenberg; George Kemble
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-09       Impact factor: 11.205

8.  The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus.

Authors:  Amorsolo L Suguitan; Michael P Marino; Purvi D Desai; Li-Mei Chen; Yumiko Matsuoka; Ruben O Donis; Hong Jin; David E Swayne; George Kemble; Kanta Subbarao
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

9.  Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus.

Authors:  M L Herlocher; H F Maassab; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.

Authors:  Shufang Fan; Yuwei Gao; Kyoko Shinya; Chris Kafai Li; Yanbing Li; Jianzhong Shi; Yongping Jiang; Yongbing Suo; Tiegang Tong; Gongxun Zhong; Jiasheng Song; Ying Zhang; Guobin Tian; Yuntao Guan; Xiao-Ning Xu; Zhigao Bu; Yoshihiro Kawaoka; Hualan Chen
Journal:  PLoS Pathog       Date:  2009-05-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.